英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
46072查看　46072　在百度字典中的解释百度英翻中〔查看〕
46072查看　46072　在Google字典中的解释Google英翻中〔查看〕
46072查看　46072　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • The SGLT2 Diet: Eating to Support Your Diabetes Medication
    Food can either support your treatment or get in its way, and for people taking SGLT2 inhibitors, certain dietary choices can help maximize the benefits while reducing side effects
  • SGLT2 Inhibitors: What They Are, Uses Side Effects
    SGLT2 inhibitors lower blood sugar by causing your kidneys to remove glucose through your pee Learn more about this treatment for Type 2 diabetes
  • Precision medicine in type 2 diabetes: targeting SGLT2 . . .
    To address this gap and support treatment decisions in clinical practice, we developed and validated a model to predict individual-level kidney protection benefit through the use of SGLT2 inhibitors
  • SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting . . .
    Originally developed for use in type 2 diabetes mellitus (T2DM), sodium–glucose co-transporter-2 (SGLT2) inhibitors demonstrated diverse cardiovascular- and kidney-protective effects in large outcome trials Their subsequent approval as a treatment for chronic kidney disease (CKD) marked a pivotal shift in the landscape of CKD management Further to this, the approval of dapagliflozin and
  • Frontiers | Benefits of SGLT2 inhibitors in patients with . . .
    SGLT2 inhibitors have transformed the care of patients with diabetes, chronic kidney disease (CKD), and cardiovascular disease Nevertheless, the efficacy of
  • USE OF SGLT2 INHIBITORS IN THE MANAGEMENT OF PATIENTS WITH . . .
    is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) into treatment of patients with heart failure
  • 11. Chronic Kidney Disease and Risk Management: Standards of . . .
    Moreover, recent data support the notion that SGLT2 inhibitors reduce oxidative stress in the kidney by >50% and blunt increases in angiotensinogen as well as reduce NLRP3 inflammasome activity (92–94) Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95–100)
  • Data Support In-Hospital Start of SGLT2 Inhibitors for HF
    A randomized trial of in-hospital initiation of an SGLT2 inhibitor in patients with heart failure missed its endpoint, but a meta-analysis with this trial showed benefit that included all-cause death
  • Sodium-Glucose Transport 2 (SGLT2) Inhibitors
    Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, have transformed the management of type 2 diabetes mellitus (T2DM) by providing glucose-lowering efficacy together with cardiovascular and renal protection Initially approved as adjuncts to diet and exercise for glycemic control, these agents now have expanded





中文字典-英文字典  2005-2009